Dongfang Wealth Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) an increase in holdings rating. The main reasons for the rating include: 1) core products returning to strong growth; 2) main products have unique advantages; 3) attaching great importance to the development layout of traditional Chinese medicine tablets and traditional Chinese medicine formula granules; 4) continuous improvement in cost control and continuous increase in net interest rates. (Mainichi Keizai Shimbun)
东方财富证券4月19日发布研报称，给予佐力药业（300181.SZ）增持评级。评级理由主要包括：1）核心产品回归强劲增长；2）主打产品具有独特优势；3）高度重视中药饮片及中药配方颗粒发展布局；4）费控持续改善净利率不断提升。（每日经济新闻）
Dongfang Wealth Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) an increase in holdings rating. The main reasons for the rating include: 1) core products returning to strong growth; 2) main products h
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated